Title
Category
Credits
Event date
Cost
  • Diabetes
  • 1.00 AAFP Prescribed
  • 1.00 AOA Category 2-A
$0.00
This interactive, case-based activity provides education on the clinical characteristics of the GLP-1 RAs, how they differ from each other, and the rationale and guidance for their use with patients with Type 2 Diabetes (T2D). Participants will encounter clinical case scenarios on personalizing treatment with GLP-1 RAs, taking into account patient characteristics and preferences, adherence, and management of side effects.Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • 1.25 AAFP Prescribed
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
$0.00
In this 19 minute presentation, Dr. Gloria Sanchez sheds light on critical and often neglected aspects of opioid use disorder (OUD) stigma encountered by health care professionals and people living with OUD. The medical model of addiction frames addiction as a treatable chronic medical condition rather than a personal failure. While Social Determinants of Health (SDOH) contribute to OUD stigma, we learn what steps providers can take to reduce the negative impacts of stigma and improve OUD care and outcomes.
$0.00
These activities are part of the education provided for the California Residency Program Collaborative (CRPC) and available to providers to improve education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medications for opioid use disorder. The CRPC series offers terrific education modules to help providers identify and serve their patients with OUD/SUD. For more information, go to www.familydocs.org/crpc.
  • S.U.D
  • Pain Management
  • 3.00 AAFP Prescribed
  • 3.00 AMA PRA Category 1 Credit™
$0.00
The curriculum, Pain Management and Opioids: Balancing Risks and Benefits, meets the latest FDA Blueprint and CDC guidelines for opioid prescribing and pain management, and includes the impact of COVID-19, new pain relieving treatments, and telehealth. This education includes California state-specific information and counts towards California CME requirements for pain management and opioid prescribing practices.This activity meets the new DEA CME requirement when renewing or obtaining your DEA license.
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
People with substance use disorders (SUD) are coming to the office, whether we know it or not. Let's treat SUD/OUD (opioid use disorder) as we would treat any other medical condition: with compassion and good medicine. In this webinar you’ll learn to recognize stigma, communicate more effectively, and be more confident in choosing Medication for OUD (MOUD). Addiction medicine is family medicine.Learning Objective:At the end of this session, learners should be able to:Identify common barriers to health care practitioners beginning MOUD
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
While gains have been made in reducing stigma around certain conditions, like depression and obesity, little progress has been made in removing the stigma around substance use disorders. The public and even health care providers continue to blame patients for their disease even though there is clear consensus that addiction is a complex brain disorder and not the result of moral weakness and flawed character.When people with addiction are stigmatized and rejected, especially by those within healthcare, it only contributes to the vicious cycle that entrenches their disease.
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
Dr. Trotzky-Sirr will explain the three medicines typically prescribed for OUD, and guide you through specific resources and protocols so you can get started saving lives right away.Learning Objectives:At the end of this session, learners should be able to:Describe different modalities of initiating MOUD in the setting of fentanylIdentify which patients are appropriate for primary care management versus those who need a referral to addiction specialists
  • S.U.D
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
$0.00
Don’t fear what you already know how to do! Just as we manage other patients battling chronic conditions, we can manage OUD (opioid use disorder) patients too. It isn’t only the patients, but also their families, their loved ones, their co-workers, and their community that are suffering from the effects of addiction. There is nothing else in Family Medicine where you can make such a huge difference in a person’s life and the lives of all those around them – than supporting someone battling addiction. Dr.
  • S.U.D
$0.00
As of June 27, 2023, DEA registrants are to have completed a total of at least 8 hours of training on treatment and management of patients with opioid or other substance use disorders. This 8-hour activity meets training requirements of the 2023 MATE (Medication Access and Training Expansion) Act.This activity brings together accredited CAFP SUD enduring activities into an 8-hour package:

Pages